Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation)

NCT00827138 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myeloid Leukemia

Interventions

DRUG: DCC-2036

Sponsor

Deciphera Pharmaceuticals, LLC